Phase 2 PTSD Trial, Recruiting NCT06639061 Sponsor: Tel Aviv University Condition: PTSD
Back to Ptsd

Phase 2 PTSD Trial, Recruiting

NCT06639061
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 20 and 65 years old.
  • People who have been diagnosed with PTSD according to the DSM-5 standard, confirmed through a specific structured clinical interview called the CAPS-5.
  • People whose CAPS-5 interview score is 33 or higher.
  • People who experience intrusive symptoms — such as flashbacks, nightmares, or unwanted distressing memories — at least 3 times per week.
  • People who meet the standard safety requirements for having an MRI scan.

Who may not be able to join:

  • People who have been diagnosed with Complex PTSD or a personality disorder.
  • People who have a psychotic disorder, bipolar disorder, autism, or an intellectual disability.
  • People who are taking psychiatric medications, unless the medication is one listed in the study protocol and the dose has been stable for the past three months and will not change during the study (confirm with trial site).
  • People who do not meet the standard safety guidelines for TMS (a type of brain stimulation) research (confirm with trial site).
  • People currently using any of the following substances: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, MDMA (ecstasy), PCP (angel's dust), ketamine, GHB, alcohol, or theophylline.
  • People who have epilepsy or who take anti-epileptic medications.
  • People who have had a traumatic head injury or head surgery.
  • People who have any metal implanted in their body — except for dental fillings, amalgam, or orthodontic fittings that have been approved as safe for MRI — or who have implanted electrodes or a pacemaker.
  • People who experience migraines.
  • People who are pregnant.
  • People who have hearing problems.
  • People who have consumed alcohol within 24 hours before a TMS session.
  • People who have had repeated episodes of fainting with loss of consciousness, or any such episode within the past year.
  • People who do not meet the standard safety requirements for having an MRI scan.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yair Bar-Haim, PhD, Tel Aviv University

Phone: 972-3-6405465

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tel Aviv University
Registry
ClinicalTrials.gov
Start date
1 November 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov